Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation

Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2021-03, Vol.56 (3), p.596-604
Hauptverfasser:	Sugita, Junichi, Kamimura, Tomohiko, Ishikawa, Takayuki, Ota, Shuichi, Eto, Tetsuya, Kuroha, Takashi, Miyazaki, Yasuhiko, Kumagai, Hiroaki, Matsuo, Keitaro, Akashi, Koichi, Taniguchi, Shuichi, Harada, Mine, Teshima, Takanori
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/100 692/699/1541/1990/283/1897 692/700/565/2319 Blood Cell Biology Cyclophosphamide Dosage and administration Graft versus host reaction Graft vs Host Disease - prevention & control Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Histocompatibility antigen HLA Humans Immunosuppressive agents Internal Medicine Leukocytes (neutrophilic) Medicine Medicine & Public Health Mycophenolate mofetil Mycophenolic acid Peripheral blood Peripheral Blood Stem Cell Transplantation Prevention Prophylaxis Prospective Studies Public Health Risk factors Stem cell transplantation Stem Cells Survival Tacrolimus Transplantation Transplantation Conditioning
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!